Efficacy and safety of bivalirudin without post-procedure infusion in patients with coronary heart disease during elective percutaneous coronary intervention:a real-world study  

作　　者：Ping Wang Xin Zhao Qimin Yuan Xiaoxue Yu Lin Yang Xiaozeng Wang 

机构地区：[1]Department of Cardiology,General Hospital of Northern Theater Command,Shenyang,Liaoning 110016,China [2]Department of Pharmacy,The People's Hospital of Langfang,Langfang,Hebei 065000,China [3]Department of Cardiology,The Second Affiliated Hospital of Dalian Medical University,Dalian,Liaoning 116023,China

出　　处：《Chinese Medical Journal》2022年第1期116-118,共3页中华医学杂志（英文版）

摘　　要：To the Editor:Antithrombotic therapy is essential to prevent adverse ischemic events during and after percutaneous coronary intervention(PCI).Anticoagulation during PCI is most commonly achieved with heparin or bivalirudin.Bivalirudin does not activate platelets,does not bind to plasma proteins and has linear pharmaco-kinetics with a short half-life of 25 min.[1,2,3]These characteristics indicate that bivalirudin may be an ideal anticoagulation drug for PCI.Prior trials which were about patients with acute myocardial infarction(AMI)undergoing primary PCI showed that a bivalirudin-based anticoagulation strategy decreased the risk of major bleeding,but it was associated with an increased risk of acute stent thrombosis(ST)compared with a heparin-based strategy.[4]It was considered that short half-life of bivalirudin and delayed onset of platelet P2Y12 receptor inhibitor in AMI patients led to a blank period of antithrombotic therapy after primary PCI.

关 键 词：patients CORONARY INFUSION 

分 类 号：R541.4[医药卫生—心血管疾病]